Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.

ABSTRACT:

Background

Despite the recent progress in the treatment and outcome of Non Small Cell Lung Cancer (NSCLC), immunotherapy has still significant limitations reporting a significant proportion of patients not benefiting from therapy, even in patients with high PD-L1 expression. We have previously demonstrated that the combined inhibition of MEK and PD-L1 in NSCLC patients derived three dimensional cultures exerted significant synergistic effect in terms of immune-dependent cancer cell death. However, subsequent experiments analyzing the expression of Indoleamine 2,3-dioxygenase-1 (Ido-1) gene expression demonstrated that Ido-1 resulted unaffected by the MEK inhibition and even increased after the combined inhibition of MEK and PD-L1 thus representing a potential escape mechanism to th

SUBMITTER: Della Corte CM 

PROVIDER: S-EPMC9682755 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature